XTRA:MBG
XTRA:MBGAuto

Is Mercedes-Benz Group Fairly Priced After Recent Gains and EV Strategy Headlines in 2025?

If you’re standing at the crossroads, trying to decide what to do with Mercedes-Benz Group stock, you're not alone. Over the past few years, this iconic automaker has revved up some impressive long-term gains while teasing investors with its recent price moves. Just this month, shares have edged up by 1.1%, accelerating to 4.3% over the past 30 days. While the one-year performance sits flat at 0.0%, those who’ve been in the driver’s seat for the past five years are sitting on a remarkable...
XTRA:TMV
XTRA:TMVSoftware

TeamViewer (XTRA:TMV) Margin Beat Reinforces Bullish Narratives Despite Share Price Discount

TeamViewer (XTRA:TMV) posted robust earnings, with net profit margins rising to 17.8% from 16.3% a year ago. Over the last five years, annual earnings have grown by 11.1%, while the most recent twelve months saw a 19.6% jump in earnings. With earnings forecast to grow by 14.1% per year and revenue expected to increase at 7.7% annually, outpacing the broader German market, investors have plenty of growth drivers to watch. At the same time, share price and financial stability risks remain part...
XTRA:RWE
XTRA:RWERenewable Energy

Will Reef Cubes at Rampion Offshore Wind Farm Redefine RWE's (XTRA:RWE) Sustainable Investment Narrative?

Offshore wind specialist RWE and ARC Marine recently installed eco-engineered Reef cubes as undersea protection for turbine foundations at the Rampion Offshore Wind Farm, marking a global first in combining energy infrastructure with marine habitat creation. This innovative approach offers a nature-inclusive alternative to traditional scour protection, supporting marine biodiversity and reflecting a broader energy sector emphasis on environmental sustainability. We’ll examine how this...
XTRA:MUM
XTRA:MUMSoftware

Mensch und Maschine (XTRA:MUM) Margin Surprise Reinforces Bullish Narratives, Dividend Sustainability Still in Question

Mensch und Maschine Software (XTRA:MUM) delivered another quarter of profitability focus, posting a net profit margin of 12.6% compared to 9.4% a year ago. Over the past five years, earnings have grown at an annual rate of 10.9%. Forecasts now call for earnings growth of 14.76% per year, with revenue also expected to climb 9.4% annually, outpacing the broader German market. With shares currently trading at €42.7, investors are weighing the positive growth outlook against the ongoing question...
XTRA:BMW
XTRA:BMWAuto

BMW (XTRA:BMW) Valuation: Is There More Upside After Recent Share Price Pullback?

Bayerische Motoren Werke (XTRA:BMW) shares have seen moderate movement over the past month, with a slight pullback of 2%. The stock’s longer-term performance, however, presents a stronger picture for the German automaker. See our latest analysis for Bayerische Motoren Werke. While BMW’s share price has seen a modest retreat recently, its strong 12.4% total shareholder return over the past year suggests the company’s long-term momentum remains positive. This comes even as the broader auto...
XTRA:BAYN
XTRA:BAYNPharmaceuticals

Is There Now an Opportunity in Bayer After Share Price Rose 42% in 2024?

If you are sizing up what to do with Bayer stock right now, you are not alone. Bayer has been on the minds of many investors recently, especially after a year that saw its share price rocket higher by almost 42% year to date, even as it recovered only modestly in the last week and month (up 1.0% and 0.2%, respectively). Despite steady long-term declines and a tough last three years, with shares down 44%, the rebound so far in 2024 has led many to wonder if the turnaround signals a true...
XTRA:TKMS
XTRA:TKMSAerospace & Defense

ThyssenKrupp Marine Systems (XTRA:TKMS): Assessing Valuation After Recent Share Price Drop

ThyssenKrupp Marine Systems (XTRA:TKMS) shares finished the latest trading session down 5% at €74.35. Investors are watching closely for updates or catalysts that could shed light on the company’s outlook and valuation. See our latest analysis for ThyssenKrupp Marine Systems. After a sharp 5% drop in the latest session, ThyssenKrupp Marine Systems’ year-to-date share price return stands at -8.3%, reflecting some fading momentum amid market uncertainty. The share price swings are reminding...
XTRA:TKA
XTRA:TKAMetals and Mining

Why thyssenkrupp (XTRA:TKA) Is Down 28.4% After Spinning Off Naval-Defense Unit TKMS

Earlier this week, thyssenkrupp completed the spin-off of its naval-defense unit, TKMS, which began trading as an independent company at €60 per share and reached as much as €99.99, establishing a market capitalization of US$4.44 billion at the opening price. This move enables thyssenkrupp to sharpen its focus on core defense operations and respond to increasing European defense expenditures. We will explore how the separation of the naval-defense business and sharper defense focus influence...
HMSE:S9I
HMSE:S9IElectronic

High Growth Tech Stocks in Europe to Watch October 2025

In recent weeks, the European market has shown mixed performance with the pan-European STOXX Europe 600 Index rising slightly due to dovish signals from U.S. Federal Reserve officials and easing trade tensions between the U.S. and China, while individual country indices like Germany's DAX have experienced declines amid industrial output contractions. In this evolving landscape, identifying high-growth tech stocks in Europe requires a keen eye on companies that demonstrate resilience and...
XTRA:GXI
XTRA:GXILife Sciences

Should FDA Approval of Lasix ONYU Prompt a Closer Look at Gerresheimer’s (XTRA:GXI) Growth Path?

On October 13, 2025, SQ Innovation received FDA approval for Lasix ONYU, a combination product featuring Gerresheimer’s proprietary on-body infusor for at-home subcutaneous drug delivery in select congestive heart failure patients. This milestone showcases Gerresheimer’s technological capabilities in advanced drug delivery devices and highlights its growing position as a full-service partner to pharmaceutical companies embracing home-based care. Next, we’ll explore how the FDA-backed rollout...
XTRA:SRT3
XTRA:SRT3Life Sciences

Sartorius (XTRA:SRT3) Is Up 14.1% After Upgraded 2025 Guidance Following Strong Q3 Results and MATTEK Deal Has The Bull Case Changed?

Sartorius Aktiengesellschaft has recently reported its third quarter and nine-month results for 2025, highlighted by increased sales to €843.2 million and a rise in net income to €43.8 million, also raising its full-year 2025 financial guidance after considering the MATTEK acquisition and market conditions. An interesting point is Sartorius' management specifically sharpened its guidance, factoring in strong year-to-date performance, new tariffs, acquisition impact, and comparisons to the...
XTRA:BAS
XTRA:BASChemicals

Assessing BASF (XTRA:BAS) Valuation as Shares Rebound and Cost-Cutting Plans Take Shape

BASF (XTRA:BAS) has steadily drawn attention among investors curious about the trajectory of the stock after recent performance data. With returns fluctuating over the month and past 3 months, market watchers are assessing BASF’s direction in today's environment. See our latest analysis for BASF. BASF’s share price has regained some ground recently, with a 3.82% jump over the last week hinting at renewed interest following months of mixed momentum. Over the past year, however, the 1-year...